Zafrens is at the forefront of integrating advanced technologies to revolutionize drug discovery and cellular analysis. The company employs nanofabrication techniques to manipulate and analyze cells with unprecedented resolution and throughput, enabling the democratization of drug discovery across various modalities. Their innovative approach includes the use of Active-seq and Active-Drug-seq, which map the molecular states of cells to their functional manifestations, allowing for simultaneous phenotypic and molecular high-throughput screening. This capability facilitates the exploration of complex co-cultures at single-cell resolution, providing a comprehensive understanding of cellular behavior and interactions.

The technical stack of Zafrens supports the execution of 50,000 to 200,000 simultaneous experiments in nanoliter volumes, significantly enhancing the scale and efficiency of biological experimentation compared to traditional methods. Their proprietary addressing mechanism allows for individual access to assay volumes, enabling researchers to conduct millions of experiments without the need for expensive robotics. This transformative platform not only connects biological and chemical data but also opens new avenues for scientific discovery, particularly in small molecule drug discovery and T cell analysis, while also exploring antibody-epitope mapping. The integration of these technologies positions Zafrens to lead advancements in life sciences and contribute to a healthier future.

United States

Zafrens is a therapeutics company pioneering an ultra-high throughput platform to isolate, culture, image, and sequence millions of cells per day. The proprietary platform allows for full characterization of diverse cell populations, as well as directly correlating molecular profiles (DNA, RNA, protein) to cell phenotype and function. The company’s mission is to unlock the full story of every cell to accelerate drug discovery.

Zafrens

Company Details